Our vision
At Galibra Neuroscience, our unwavering mission is to lead the forefront of innovation in gene therapy, dedicated to developing safe and effective treatments for GABA-related disoders.
We are committed to the timely translation of cutting-edge drug development, ensuring that our progress meets the urgent needs of patients.
Patients’ well-being is the bedrock of our core value. By brining state-of-the-art technology directly to patients, we aim to empower lives, foster neurological harmony, and set new standards for excellence in personalized healthcare.
About Us
GALIBRA NEUROSCIENCE
Galibra Neuroscience was founded in 2023 by a clinician and a scientist at Boston Children’s Hospital affiliated with Harvard Medical School. Our founders have over 25 years of experience in clinical care and translational research. We are directing our knowledge to improve patient lives.
Our Science
GABA (gamma-aminobutyric acid) is the major inhibitory neurotransmitter in our brain.
GABA keeps our neural communication in check, preventing over-excitation. The level of GABA in healthy brains is highly regulated (i.e., balanced).
Over 20 genes are responsible for the post-release or recycling of GABA. Genetic variants of these genes lead to GABA imbalance, the root cause of many rare pediatric disorders.
Because we know precisely where these genes are and what they do, replacing them (as in the form of gene replacement therapy) to achieve GABA balance is a realistic therapeutic goal.
Our name stems from our scientific mission ‘to restore the GABA balance for neurological well-being’
GA represents our laser focus on GABA-disorders
LIBRA symbolizes balance, harmony, and equilibrium
Why GALIBRA?
We leverage strong partnerships with leading academic institutes and patient advocacy groups to streamline bench to bedside translation of novel disease-modifying therapies.
Our approach is RAPID:
- R - research-oriented: our data-driven approach maximizes safety and efficacy
- A - accessibility: we work closely with patient communities
- P - patient-focused: we aim to improve patient quality of life
- I - innovative: our work stems from state-of-the-art technology
- D - deep knowledge: we understand detailed disease mechanisms
Pipeline
Leadership
Alexander Rotenberg, MD PhD
Co-Founder
Henry Lee, MPhil, PhD
Co-Founder
Amber Freed
Chief Development Officer
Director
Brad Hoffman
Business Development and Fundraising
Advisors
Phillip Pearl, MD
Clinical Study Advisor
